Hantavirus global briefing — September 6, 2026: Germany records 6 weekly notifications while vaccine evidence remains preclinical

Executive read

The freshest verified human surveillance signal is Germany's week-35 notification table. The Robert Koch Institute (RKI) recorded 6 hantavirus notifications in week 35, 198 notifications across weeks 1–35 of 2026, and 206 in the same period of 2025. The bulletin was published on 3 September, with data status on 2 September. 1

The European Centre for Disease Prevention and Control (ECDC) published its week-36 threat report on 4 September, covering 29 August–4 September. The listed threats include Ebola, West Nile virus, dengue, chikungunya, Crimean-Congo haemorrhagic fever, malaria, Middle East respiratory syndrome and other conditions; the published list contains no hantavirus or Andes-virus item. 2

Two new September research and response signals add preparedness information. The University of Liverpool describes rapid contact recruitment, sampling and favipiravir coordination during the Andes outbreak. A 2 September preprint reviews DNA and mRNA vaccine development and places mRNA candidates at the preclinical stage. 3 4

A current global human denominator remains unavailable from accessible, date-bounded material in this scan. Germany supplies a comparable national count; the ECDC bulletin supplies a regional threat-list result; WHO and CDC provide older status boundaries for the closed cruise-linked event and its response.

Human surveillance

Germany: six notifications in week 35

Jurisdiction and period	Notifications	Same-window comparison	What the number describes
Germany, week 35 of 2026	6	Weekly count	Hantavirus notifications received for the reporting week. 1
Germany, weeks 1–35 of 2026	198	—	Notifications accumulated through the RKI data status of 2 September 2026. 1
Germany, weeks 1–35 of 2025	206	8 more than 2026	RKI's same-window comparator. 1

Germany's weekly count fell from 10 notifications in week 34 to 6 in week 35. The year-to-date total remains eight notifications below the 2025 comparison. The RKI table counts notifications that meet the applicable reference definition and were transmitted by the stated data status. Germany's figures describe one national reporting stream; they do not produce a Europe-wide or global incidence estimate. 1

ECDC: the week-36 threat list carries no hantavirus item

ECDC's week-36 report covers 29 August–4 September and was published on 4 September. The issue summary names Ebola, SARS-CoV-2 variant classification, West Nile virus, Crimean-Congo haemorrhagic fever, dengue, chikungunya, Vibrio, Middle East respiratory syndrome, malaria, influenza A(H9N2) and respiratory-virus epidemiology among its topics. Hantavirus and Andes virus do not appear in that published summary. 2

The ECDC result is a bounded threat-list observation. National surveillance remains necessary for diseases that do not appear in a weekly threat bulletin. The current European picture therefore contains a fresh German count alongside an ECDC bulletin without a hantavirus item.

The Americas, Asia-Pacific and other regions

This scan did not verify a new authoritative human denominator with a defined reporting cut-off for the Americas, Asia-Pacific or another region. The available evidence supports a country-level German signal and a regional bulletin result rather than a single global total.

The WHO record for the M/V Hondius Andes-virus outbreak remains a separate, closed event. WHO's 2 July update records 13 cases, including 12 laboratory-confirmed cases and one probable case, and 3 deaths. All identified contacts completed 42-day follow-up. WHO reports that 317 high-risk contacts completed quarantine and monitoring, 336 low-risk contacts completed self-monitoring, and no additional secondary cases were detected. WHO concludes that the outbreak no longer poses a public health risk and expects no further related transmission. 5

The cruise-linked total supplies a closure boundary for one Andes-virus cluster. The total should remain separate from routine rodent-associated surveillance in Germany, Chile, Argentina and other endemic settings.

Official posture and response capacity

The accessible CDC situation page is an archived record dated 7 July 2026. The page describes the May 2026 cruise-linked outbreak rather than a September alert. The archive status makes the page useful as a record of CDC's earlier response posture, while the page supplies no current September risk-level change. 6

The University of Liverpool's 1 September account adds operational detail from the international response. Liverpool reports that 33 contacts and cases were recruited across the United Kingdom, including 26 at Arrowe Park Hospital. UKHSA's Rare and Imported Pathogens Laboratory and the MRC–University of Glasgow Centre for Virus Research analysed samples through sequencing, serology and immunological profiling. The account also says that favipiravir reached the Netherlands, Spain, France and Canada within 24 hours, and that one British patient in the Netherlands received the drug experimentally. 3

The same account describes continuing work on disease severity, transmission, asymptomatic infection and environmental contamination. Liverpool's article is an institutional response account. It does not provide a population-level estimate of transmission risk or a controlled treatment-effect result. 3

Reservoir and exposure context

The latest dated ecological signal available from the RIVM page is an update from 23 July. RIVM reports more Puumala-virus illness in Twente than in previous years, against an average of about 15 infections per year. Many affected people lived near or visited forests, nature areas or meadows, and possible exposure occurred while cleaning or sweeping sheds contaminated with mouse droppings. RIVM raises a possible mast-year explanation, in which abundant tree nuts support larger rodent populations. 7

The RIVM update gives an exposure setting and a possible ecological mechanism. The page reports no rodent-abundance count, reservoir-infection prevalence estimate or environmental sampling result. The present ecological layer therefore remains qualitative and local rather than a September measurement of rodent risk across Europe or globally. 7

Research watch

The current research window is 31 August–6 September 2026 by native publication or posting date. The two entries answer different questions: one records how response teams generated usable outbreak evidence, and the other assesses how vaccine platforms are moving toward clinical testing.

Liverpool's rapid-response evidence pipeline

Team and institution: Tom Fletcher, Lance Turtle, Saye Khoo, Tom Solomon, Sam Tweed and colleagues at the University of Liverpool, Liverpool School of Tropical Medicine, UKHSA and partner institutions.
Date and type: Published 1 September 2026; institutional research and response account rather than a peer-reviewed outcome study. 3
Scope: 33 UK contacts and cases were recruited, including 26 at Arrowe Park Hospital. Samples underwent sequencing, serology and immunological profiling at UKHSA and the University of Glasgow. 3
Quantitative result: Favipiravir was supplied to four countries within 24 hours: the Netherlands, Spain, France and Canada. One British patient in the Netherlands received experimental treatment. 3
Practical use: The response created a combined contact, clinical, laboratory and environmental evidence stream during an active investigation. That arrangement can support questions about transmission, asymptomatic infection and disease severity.
Evidence limit: The account reports activities and recruitment. It gives no controlled comparison, treatment-effect estimate or population denominator for the international outbreak. 3

DNA and mRNA vaccine review

Authors and institution: Karolina Pawłuszkiewicz, Anita Faltus, Martyna Zdych, Emilia Nowak and Emil Paluch.
Date and type: Posted 2 September 2026; non-peer-reviewed review preprint. 4
Scope: The review examines DNA and mRNA vaccine design, delivery, immunogenicity, safety and translational development, with emphasis on Hantaan virus, Puumala virus and Andes virus. 4
Quantitative result: The preprint reports no new clinical or experimental effect estimate because it is a review. Its evidence summary places DNA candidates in animal studies and early clinical studies, while mRNA candidates remain supported by preclinical animal work. 4
Practical use: The review identifies multivalent design, standardized evaluation and improved correlates of protection as development priorities. Antigenic diversity limits the assumption that protection against one hantavirus will cover every strain. 4
Evidence limit: The preprint has not undergone peer review. The authors identify incomplete cross-protection, immune interference in some multivalent formulations, uncertain durability, unclear correlates of protection and the absence of a fully representative animal model as important constraints. 4

The two entries point to different preparedness bottlenecks. Liverpool's account concerns the speed and breadth of evidence collection during a real outbreak. The vaccine review concerns the distance between promising platform data and a broadly useful clinical product. Neither entry changes the current human case denominator.

Assessment and watchpoints

The evidence supports five separate watchpoints:

Germany's weekly notifications: The next RKI bulletin will show whether the fall from 10 notifications in week 34 to 6 in week 35 continues. The year-to-date comparison currently stands at 198 in 2026 versus 206 in 2025. 1
European threat-list status: A future ECDC bulletin with a hantavirus item would change the regional alert layer. Week 36 contains no such item in its published summary. 2
International alerts: A new WHO event update or CDC alert would replace the current closure and archive boundaries. WHO's latest record closes the M/V Hondius event at 13 cases and three deaths; the accessible CDC situation page is archived to 7 July. 5 6
Reservoir measurements: A dated rodent count, reservoir prevalence estimate or environmental sample would add a quantitative layer beyond RIVM's local exposure and mast-year context. 7
Clinical and vaccine readiness: The Liverpool response account supports attention to rapid sampling, laboratory coordination and treatment logistics. The vaccine preprint supports continued scrutiny of clinical validation, cross-protection and durability before interpreting platform progress as deployable protection. 3 4

The 6 September position is specific: Germany recorded 6 hantavirus notifications in week 35 and 198 through week 35, ECDC's latest threat list contains no hantavirus item, WHO's cruise-linked Andes outbreak remains closed at 13 cases and three deaths, and the newest research adds response and vaccine-readiness evidence rather than a new global denominator.